Stocks Trend Analysis: Extended Stay America, Inc. (STAY), Deere & Company (DE), Agios Pharmaceuticals, Inc. (AGIO)

Extended Stay America, Inc. (STAY) continued its downward trend with the stock declining -1.07% or $-0.17 to close the day at $15.77 on active trading volume of 2.2M shares, compared to its three month average trading volume of 1.08M. The Charlotte North Carolina 28277 based company has been outperforming the lodging group over the past 52 weeks, with the stock gaining 12.9%, compared to the industry which has advanced 9.97% over the same period. With RSI of 45.98, the stock should still continue to rise and get closer to its one year target estimate of $18.27, making it a hold for now.

Extended Stay America, Inc. develops, owns, and operates hotels in the United States and Canada. As of December 31, 2015, the company had 629 hotels with approximately 69,400 consisting of 626 hotels with approximately 68,900 rooms under the Extended Stay America brand; and 3 hotels with 500 rooms under the Extended Stay Canada brand. It serves customers in the mid-priced extended stay segment. Extended Stay America, Inc. was founded in 1995 and is headquartered in Charlotte, North Carolina.

Deere & Company (DE) retreated with the stock falling -1.22% or $-1.3 to close at $105.19 on light trading volume of 2.2M compared its three months average trading volume of 3.15M. The Moline Illinois 61265 based company operating under the Farm & Construction Machinery industry has been trending up for the last 52 weeks, with the shares price now 46.66% up for the period and up by 2.09% so far this year. With price target of $101.35 and a 54.19% rebound from 52-week low, Deere & Company has plenty of upside potential, making it a hold with a view buy.

Deere & Company, together with its subsidiaries, manufactures and distributes agriculture and turf, and construction and forestry equipment worldwide. The company’s Agriculture and Turf segment provides agriculture and turf equipment, and related service parts, including large, medium, and utility tractors; loaders; combines, cotton pickers and strippers, and sugarcane harvesters; related front-end harvesting equipment; sugarcane loaders and pull-behind scrapers; and tillage, seeding, and application equipment, including sprayers, nutrient management, and soil preparation machinery. This segment also provides hay and forage equipment comprising self-propelled forage harvesters and attachments, balers, and mowers; turf and utility equipment, including riding lawn equipment and walk-behind mowers, golf course equipment, utility vehicles, and commercial mowing equipment, as well as associated implements; integrated agricultural management systems technology and solutions; and other outdoor power products. Its Construction and Forestry segment provides backhoe loaders; crawler dozers and loaders; four-wheel-drive loaders; excavators; motor graders; articulated dump trucks; landscape loaders; skid-steer loaders; and log skidders, feller bunchers, log loaders, log forwarders, log harvesters, and related attachments that are used in construction, earthmoving, material handling, and timber harvesting applications. The company’s Financial Services segment finances sales and leases of new and used agriculture and turf equipment, and construction and forestry equipment. This segment also provides wholesale financing to dealers of the foregoing equipment; finances retail revolving charge accounts; and offers extended equipment warranties. The company markets its products primarily through independent retail dealer networks and retail outlets. Deere & Company was founded in 1837 and is headquartered in Moline, Illinois.

Agios Pharmaceuticals, Inc. (AGIO) failed to extend gains with the stock declining -9.94% or $-4.72 to close the day at $42.78 on lower than average trading volume of 2.19M shares, compared to its three month average trading volume of 815.53K. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology companies by -18.8852% for last three months and its recent losses have trimmed gains to 2.52% YTD, versus the biotechnology industry which is up 3.69% for the same period. The RSI of 41.69 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; Celgene International II Sarl to develop and commercialize AG-881 products; and Abbott and Celgene Corp. to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System. The company was founded in 2007 and is based in Cambridge, Massachusetts.

 

Stocks Trend Analysis: Fairpoint Communications, Inc. (FRP), Rexnord Corporation (RXN), Agios Pharmaceuticals, Inc. (AGIO)

Fairpoint Communications, Inc. (FRP) continued its downward trend with the stock declining -1.04% or $-0.2 to close the day at $19.05 on light trading volume of 1M shares, compared to its three month average trading volume of 268.14K. The Charlotte North Carolina 28202 based company has been outperforming the telecom services – domestic group over the past 52 weeks, with the stock gaining 12.39%, compared to the industry which has advanced 20.09% over the same period. With RSI of 73.56, the stock should still continue to rise and get closer to its one year target estimate of $15.5, making it a hold for now.

FairPoint Communications, Inc. provides communications services to business, wholesale, and residential customers in the United States. It provides high capacity data services, including optical, Ethernet, IP services, and Ethernet virtual circuit technology for cellular backhaul; and private line special access services, as well as hosted primary branch exchange services over its Ethernet network. The company also offers Internet services, including cable modem Internet service, and fiber to the home and wireless Internet access services; and data center colocation services. In addition, it provides local calling services, such as basic local lines and local private lines; long distance services; and 9-1-1 Services. Further, the company offers network transport services, including special access services, such as DS-1 and DS-3 services; and high speed digital services comprising Ethernet-based services provisioned over fiber and copper facilities, as well as network switched, intrastate, and intrastate access services. Additionally, it publishes telephone directories; and provides video services by reselling DirectTV content, as well as offers cable and IP television video-over-digital subscriber line services. The company also provides project-based implementation support services. As of June 30, 2016, it operated approximately 311,000 broadband subscribers; 15,100 Ethernet circuits; and 389,000 residential voice lines in 17 states. The company was incorporated in 1991 and is headquartered in Charlotte, North Carolina.

Rexnord Corporation (RXN) retreated with the stock falling -1.23% or $-0.26 to close at $20.84 on light trading volume of 0.99M compared its three months average trading volume of 688.98K. The Milwaukee Wisconsin 53204 based company operating under the Diversified Machinery industry has been trending up for the last 52 weeks, with the shares price now 11.44% up for the period and up by 15.01% so far this year. With price target of $21 and a 48.43% rebound from 52-week low, Rexnord Corporation has plenty of upside potential, making it a hold with a view buy.

Rexnord Corporation designs, manufactures, and markets process and motion control, and water management products worldwide. The company operates in two segments, Process & Motion Control Platform and Water Management Platform. The Process & Motion Control Platform segment designs, manufactures, markets, and services engineered mechanical components used in complex systems. It offers table top conveying chain and related accessories, gearing and gear drives, conveying equipment, industrial chains, and custom assemblies; shaft management products; assemblies; and aerospace components, specialized gears, and related products. The company offers its products under Rexnord, Rex, Addax, Euroflex, Falk, FlatTop, Link-Belt, Omega, PSI, Shafer, Stearns, Thomas, and Tollok brand names. This segment offers its products through distributors to food and beverage, aerospace, mining, petrochemical, energy and power generation, cement and aggregates, forest and wood products, agriculture, and general industrial and automation applications. The Water Management Platform segment designs, procures, manufactures, and markets products that provide and enhance water quality, safety, flow control, and conservation. It offers valve products, engineered water distribution solutions, specification drainage products, and site works products; water conservation products; and water and wastewater infrastructure products. The company offers its products under Zurn, Wilkins, VAG, Green Turtle, GA, Aquaflush, AquaSense, AquaVantage, AquaSpec, EcoVantage, and Zurn One brand names. This segment sells its products through independent sales representatives, plumbing wholesalers, sales agencies, and direct sales and marketing associates to customers in the commercial construction, institutional, infrastructure, and residential construction end markets in 49 countries. Rexnord Corporation was incorporated in 2006 and is based in Milwaukee, Wisconsin.

Agios Pharmaceuticals, Inc. (AGIO) continued its upward trend with the stock climbing 3.59% or $1.72 to close the day at $49.58 on lower than average trading volume of 0.99M shares, compared to its three month average trading volume of 745.54K. The Cambridge Massachusetts 02139 based company has been underperforming the biotechnology companies by 8.2549% for last three months and its recent gains have offset losses to -23.63% YTD, versus the biotechnology industry which is up 0.17% for the same period. The RSI of 38.24 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; Celgene International II Sarl to develop and commercialize AG-881 products; and Abbott and Celgene Corp. to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Stocks Buzz: Spectra Energy Corp (SE), Express, Inc. (EXPR), Agios Pharmaceuticals, Inc. (AGIO)

Spectra Energy Corp (SE) continued its upward trend with the stock climbing 0.3% or $0.12 to close the day at $40.72 on light trading volume of 3.59M shares, compared to its three month average trading volume of 5.51M. The Houston Texas 77056 based company has been outperforming the oil & gas pipelines group over the past 52 weeks, with the stock gaining 81.34%, compared to the industry which has advanced 31.12% over the same period. With RSI of 47.61, the stock should still continue to rise and get closer to its one year target estimate of $42.3, making it a hold for now.

Spectra Energy Corp owns and operates a portfolio of natural gas-related energy assets in North America. It operates through four segments: Spectra Energy Partners, Distribution, Western Canada Transmission & Processing, and Field Services. The Spectra Energy Partners segment engages in the transmission, storage, and gathering of natural gas, as well as transportation and storage of crude oil and natural gas liquids (NGLs) for customers in various regions of the United States and Canada. Its natural gas pipeline systems consist of approximately 21,000 miles of transmission pipelines; and storage capacity comprises 300 billion cubic feet (Bcf). The Distribution segment offers natural gas storage, transmission, and distribution services for residential, commercial, and industrial customers in Canada. It has approximately 40,000 miles of main and service pipelines; storage capacity of approximately 163 Bcf; and transmission system of approximately 3,000 miles of high-pressure pipeline and mainline compressor stations. The Western Canada Transmission & Processing segment provides natural gas transmission, and gas gathering and processing services; and services to natural gas producers to remove impurities from the raw gas stream, including water, carbon dioxide, hydrogen sulfide, and other substances. It also extracts, fractionates, transports, stores, and markets NGLs for western Canadian producers and NGL customers. It serves local distribution companies, end-use industrial and commercial customers, marketers, and exploration and production companies. The Field Services segment gathers, compresses, treats, processes, transports, stores, and sells natural gas; produces, fractionates, transports, stores, and sells NGLs; recovers and sells condensate; and trades in and markets natural gas and NGLs. It owns or operates approximately 67,000 miles of gathering and transmission pipeline. The company was incorporated in 2006 and is headquartered in Houston, Texas.

Express, Inc. (EXPR) grew with the stock adding 3.52% or $0.38 to close at $11.17 on active trading volume of 3.58M compared its three months average trading volume of 2.35M. The Columbus Ohio 43230 based company operating under the Apparel Stores industry has been trending down for the last 52 weeks, with the shares price now -34.56% down for the period and down by -35.36% so far this year. With price target of $12.85 and a 7.71% rebound from 52-week low, Express, Inc. has plenty of upside potential, making it a hold with a view buy.

Express, Inc. operates as a specialty apparel and accessories retailer. It offers apparel and accessories for women and men between 20 and 30 years across various aspects of lifestyles, including work, casual, jeanswear, and going-out occasions. The company sells its products through its e-commerce Website, express.com; mobile app; and franchisees Express locations in Latin America, the Middle East, and South Africa. As of January 30, 2016, it operated 653 stores in the United States, Canada, and Puerto Rico. The company was formerly known as Express Parent LLC and changed its name to Express, Inc. in May 2010. Express, Inc. was founded in 1980 and is based in Columbus, Ohio.

Agios Pharmaceuticals, Inc. (AGIO) continued its downward trend with the stock declining -12.45% or $-7.09 to close the day at $49.88 on lower than average trading volume of 3.57M shares, compared to its three month average trading volume of 733.86K. The Cambridge Massachusetts 02139 based company has been underperforming the biotechnology companies by 33.6774% for last three months and its recent gains have offset losses to -23.17% YTD, versus the biotechnology industry which is down -4.12% for the same period. The RSI of 34.55 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; Celgene International II Sarl to develop and commercialize AG-881 products; and Abbott and Celgene Corp. to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System. The company was founded in 2007 and is based in Cambridge, Massachusetts.

 

Stocks Buzz: Accuray Inc (ARAY), Agios Pharmaceuticals Inc (AGIO), OFG Bancorp (OFG)

Accuray Incorporated (ARAY) continued its upward trend with the stock climbing 5.94% or $0.3 to close the day at $5.35 on light trading volume of 0.88M shares, compared to its three month average trading volume of 680.88K. The Sunnyvale California 94089 based company has been underperforming the medical appliances & equipment group over the past 52 weeks, with the stock losing -24.11%, compared to the industry which has advanced 8.58% over the same period. With RSI of 54.27, the stock should still continue to rise and get closer to its one year target estimate of $7.83, making it a hold for now.

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Agios Pharmaceuticals, Inc. (AGIO) grew with the stock adding 0.71% or $0.45 to close at $64.22 on light trading volume of 0.88M compared its three months average trading volume of 720.55K. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 0.61% up for the period and down by -1.08% so far this year. With price target of $62.71 and a 91.7% rebound from 52-week low, Agios Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; Celgene International II Sarl to develop and commercialize AG-881 products; and Abbott and Celgene Corp. to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System. The company was founded in 2007 and is based in Cambridge, Massachusetts.

OFG Bancorp (OFG) continued its upward trend with the stock climbing 10.57% or $1.2 to close the day at $12.55 on lower than average trading volume of 0.88M shares, compared to its three month average trading volume of 272.58K. The San Juan 00918 based company has been outperforming the money center banks companies by 17.2343% for last three months and its recent gains have pushed the stock slightly up 75.35% YTD, versus the money center banks industry which is down -10.85% for the same period. The RSI of 82.35 indicates the stock is overbought at the current levels, sell for now.

OFG Bancorp, a financial holding company, provides various banking and financial services primarily in Puerto Rico. It operates in three segments: Banking, Wealth Management, and Treasury. The Banking segment offers checking, savings, and time deposit accounts; mortgage, commercial, consumer, and auto lending products; financial planning, insurance, financial service, and investment brokerage; and corporate and individual trust and retirement services. This segment operates 48 branches in Puerto Rico. The Wealth Management segment offers securities brokerage, trust, retirement planning, insurance, pension administration, and other financial services. Its securities brokerage services cover various investment alternatives, such as tax-advantaged fixed income securities, mutual funds, stocks, and bonds to retail and institutional clients. This segment also provides separately-managed accounts and mutual fund asset allocation programs; and manages and participates in public offerings and private placements of debt and equity securities, as well as provides underwriting, merger-and-acquisition, and financial restructuring advisory services. In addition, this segment is involved in the insurance agency and administration of retirement plans in the United States, Puerto Rico, and the Caribbean. The Treasury segment is involved in various treasury-related functions with an investment portfolio consisting of mortgage-backed securities, obligations of U.S. government sponsored agencies, Puerto Rico government and agency obligations, and money market instruments. OFG Bancorp was founded in 1964 and is based in San Juan, Puerto Rico.

Analyst Review Alert: Agios Pharmaceuticals Inc (NASDAQ:AGIO)

The shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) currently has mean rating of 2.25 while 1 analysts have recommended the shares as “BUY”, 4 recommended as “OUTPERFORM” and 3 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun-16 is 39.62 million by 8 analysts. The means estimate of sales for the year ending Dec-16 is 119.80 million by 8 analysts.

The mean price target for the shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) is at 62.83 while the highest price target suggested by the analysts is 90.00 and low price target is 46.00. The mean price target is calculated keeping in view the consensus of 9 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Agios Pharmaceuticals Inc (NASDAQ:AGIO) stands at -0.48 while the EPS for the current year is fixed at -3.31 by 8 analysts.

The next one year’s EPS estimate is set at -4.93 by 8 analysts while a year ago the analysts suggested the company’s EPS at -3.31.

In its latest quarter ended on 31st March 2016, Agios Pharmaceuticals Inc (NASDAQ:AGIO) reported earnings of -$0.61. The posted earnings topped the analyst’s consensus by $0.18 with the surprise factor of 22.80%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 11, 2016 Agios Pharmaceuticals Inc (AGIO) announced initial data demonstrating that AG-348 achieved proof-of-concept in an ongoing Phase 2 study (DRIVE-PK) of patients with pyruvate kinase (PK) deficiency, a rare, potentially debilitating, congenital anemia. AG-348 is a novel, first-in-class, oral activator of both wild-type (normal) and mutated pyruvate kinase-R (PKR) enzymes. AG-348 is wholly owned by Agios. Data will be presented today at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.

DRIVE-PK is the first study to evaluate the safety and efficacy of AG-348 in patients with PK deficiency. As of the March 27, 2016 data cut-off, 18 transfusion-independent patients (13 with at least one missense mutation and five with two non-missense mutations) were treated with twice-daily dosing of AG-348 for up to six months. Treatment resulted in rapid and sustained hemoglobin increases of >1.0 g/dL in nine out of 18 patients (nine of 13 patients with at least one missense mutation), ranging from 2.3–4.9 g/dL with a mean maximum hemoglobin increase of 3.4 g/dL. It is estimated that approximately 80 percent of all PK deficiency patients carry at least one missense mutation. These data support the hypothesis that AG-348 restores metabolic function and has the potential to correct the underlying defect in the red blood cells of patients with PK deficiency.

“People with PK deficiency suffer from chronic anemia and a range of other complications brought on by both their disease and existing supportive therapies, including blood transfusions and splenectomy,” said Rachael Grace, M.D., of the Dana-Farber Boston Children’s Cancer and Blood Disorder Center and a principal investigator for the study. “These data are exciting for the hematology community and patients, as they demonstrate the potential for AG-348 to provide the first disease-modifying treatment with impressive and prolonged increases in hemoglobin levels.”

“These data have established proof-of-concept for AG-348, validating our novel approach to the treatment of rare genetic metabolic disorders by correcting the underlying enzymatic defect with a small molecule,” said Chris Bowden, M.D., chief medical officer at Agios. “The rapid and sustained hemoglobin increases and well-tolerated safety profile shown in this trial to date support continued study and moving into late-stage development. In addition, these data demonstrate the important potential role that PK activation may have in transforming treatment of PK deficiency.”

The Insider Activity Don’t Lie: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (AGIO) down -20.89 per cent in the past week, is under coverage of 8 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 6 equity analysts who rate the stock have an average target price at $62.33, with individual targets ranging between $46 and $90. The shares closed last trade at $48.75, implying that analysts see shares rising about 27.86 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -24.91 down so far this year. A Chief Scientific Officer at Agios Pharmaceuticals, Inc. (AGIO) sold shares in the company in a transaction completed on Wednesday June 08, 2016. Biller Scott offloaded 27,500 shares in the company at an average price of $65 and ended up generating $1,787,500 in proceeds. Biller Scott retains 74,270 shares in the company after this transaction. A Director in the company, Cantley Lewis Clayton Jr., on Thursday May 26, 2016 collected $129,430 from the sale of 2,504 shares at $65 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering AGIO stock at the going market price of $48.75/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.48 in earnings per share (EPS). That would represent a -43.53% year-over-year decrease. Revenue for the same period is expected to arrive at $39.62M.

Earnings Roundup: In the last fiscal quarter alone, Agios Pharmaceuticals, Inc. generated around $31.28M in revenue and net income of -$0.61/share. That compares with the consensus estimate $20.94M and -$0.79/share, respectively. For the prior quarter revenue for the company hit $6.22M, with earnings at -$1.08/share.

Analyst Coverage: JP Morgan has been a brokerage house following shares of Agios Pharmaceuticals, Inc. (AGIO), so its rating change is noteworthy. The stock was upgraded to Overweight from Neutral, wrote analysts at JP Morgan, in a note issued to clients on Monday June 13, 2016. There was another key note issued by Sun Trust Rbsn Humphrey on Wednesday March 30, 2016. The firm launched coverage on AGIO at Buy.

Price Momentum: Despite the -6.2% decrease in value, the stock’s new closing price represents a -59.7% fall in value from company’s one year high of $120.96. The stock is currently holding above its 50 day moving average of $-3.16 and below its 200 day moving average of $51.03. Over the last three months and over the last six months, the shares of Agios Pharmaceuticals, Inc. (AGIO), have changed -14.82% and 48.34%, respectively.

 

Analysts: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stock is worth $62.33

Agios Pharmaceuticals, Inc. (AGIO) down -12.92 per cent in the past week, is under coverage of 8 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 6 equity analysts who rate the stock have an average target price at $62.33, with individual targets ranging between $46 and $90. The shares closed last trade at $51.97, implying that analysts see shares rising about 19.93 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -19.95 down so far this year. A Chief Scientific Officer at Agios Pharmaceuticals, Inc. (AGIO) sold shares in the company in a transaction completed on Wednesday June 08, 2016. Biller Scott offloaded 27,500 shares in the company at an average price of $65 and ended up generating $1,787,500 in proceeds. Biller Scott retains 74,270 shares in the company after this transaction. A Director in the company, Cantley Lewis Clayton Jr., on Thursday May 26, 2016 collected $129,430 from the sale of 2,504 shares at $65 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering AGIO stock at the going market price of $51.97/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.48 in earnings per share (EPS). That would represent a -43.53% year-over-year decrease. Revenue for the same period is expected to arrive at $39.62M.

Earnings Roundup: In the last fiscal quarter alone, Agios Pharmaceuticals, Inc. generated around $31.28M in revenue and net income of -$0.61/share. That compares with the consensus estimate $20.94M and -$0.79/share, respectively. For the prior quarter revenue for the company hit $6.22M, with earnings at -$1.08/share.

Analyst Coverage: JP Morgan has been a brokerage house following shares of Agios Pharmaceuticals, Inc. (AGIO), so its rating change is noteworthy. The stock was upgraded to Overweight from Neutral, wrote analysts at JP Morgan, in a note issued to clients on Monday June 13, 2016. There was another key note issued by Sun Trust Rbsn Humphrey on Wednesday March 30, 2016. The firm launched coverage on AGIO at Buy.

Price Momentum: Despite the 3.22% increase in value, the stock’s new closing price represents a -58.13% fall in value from company’s one year high of $120.96. The stock is currently holding above its 50 day moving average of $3.65 and above its 200 day moving average of $51.16. Over the last three months and over the last six months, the shares of Agios Pharmaceuticals, Inc. (AGIO), have changed -9.48% and 48.49%, respectively.

 

Pre-Market Investor’s Alert: ArcelorMittal SA (ADR)(NYSE:MT), Agios Pharmaceuticals Inc(NASDAQ:AGIO)

ArcelorMittal SA (ADR)(NYSE:MT) stock dropped -5.10% in today’s pre market session with the price of $5.02. Over the last one month and over the past three months, ArcelorMittal shares gained 7.30% and 0.76%, respectively. Furthermore, the stock has gained 25.36% since the start of this year. The company’s shares are trading 3.77% above their 50-day moving average. Additionally, ArcelorMittal has an RSI of 55.40 and beta of 2.72.

May 19, 2016, ArcelorMittal announced the launch of its tender offer to purchase for cash any and all of its outstanding 9.850% Notes due June 1, 2019 (CUSIP 03938LAM6/ ISIN US03938LAM63) (the “Notes”) on the terms and subject to the conditions set out in the offer to purchase dated May 11, 2016 (the “Offer to Purchase”) and the Notice of Guaranteed Delivery. The Offer expired at 5:00 p.m., New York City time, on May 18, 2016 (the “Expiration Time”).

Agios Pharmaceuticals Inc(NASDAQ:AGIO) stock on Friday’s pre market session gained 9.23% at price of $54.99. Over the last one month and the previous three months, Agios Pharmaceuticals Inc’s shares gained 11.76% and 26.16%, respectively. Additionally, the stock has dropped -22.44% since the beginning of 2016. The company’s shares are trading above their 20-day and 200-day moving averages by -5.47% and -12.54%, respectively.

Agios Pharmaceuticals, Inc. (AGIO) June 9, 2016 announced the initial data from the Phase 1 integrated single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of AG-519 in healthy volunteers at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen. These data provide early proof-of-mechanism for AG-519, a potent, oral, selective second pyruvate kinase-R (PKR) activator that is wholly owned by Agios. Agios is also developing AG-348, a first-in-class, oral PKR activator that is being evaluated in an ongoing Phase 2 study, DRIVE-PK.

In this Phase 1 study, dosing of AG-519 over 14-days in healthy volunteers resulted in a dose-dependent increase in PKR activity as evidenced by a substantial increase in ATP (adenosine triphosphate) and decrease in 2,3-DPG  (2,3-diphosphoglycerate) levels, which are important biomarkers of PKR activation in healthy volunteers. These data support the hypothesis that AG-519 enhances PKR activity and has the potential to correct the underlying defect of pyruvate kinase (PK) deficiency, a rare, potentially debilitating, congenital anemia.

“Achieving proof-of-mechanism for AG-519, our second PKR activator, further advances Agios’ novel approach to the treatment of rare metabolic disorders,” said Chris Bowden, M.D., chief medical officer of Agios. “These Phase 1 data from AG-519 bring us closer to our goal of delivering the first disease-modifying treatment for patients with PK deficiency.”

Results from the Completed SAD Portion of the Phase 1 Study

Four cohorts with doses of AG-519 ranging from 50 mg to 1250 mg were tested against placebo in 32 healthy volunteers.

AG-519 demonstrated a favorable safety profile in all doses tested. There were no serious adverse events (SAEs) reported, with all adverse events (AEs) being mild to moderate, and the most common being headache. In addition, there were no early discontinuations due to AG-519 and the maximum tolerated dose was not reached.

Mean decreases in blood 2,3-DPG levels up to 43 percent from baseline were observed in the SAD cohorts, reaching minimum levels after 24 hours. As expected, ATP levels did not change after a single dose of AG-519, consistent with SAD findings from AG-348.  Healthy volunteers receiving placebo showed no changes in 2,3-DPG or ATP levels.